# Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention

Study · id `cardio:ct-nct06682351` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06682351](<https://clinicaltrials.gov/study/NCT06682351>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06682351

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT06682351. Randomized; no masking; primary purpose treatment. Start 2024-11 (anticipated); primary completion 2027-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT06682351, source copy `cardio:ctgov-nct06682351-2024-11-12`, retrieved 2026-10-26)
- Planned start: 2024-11 (anticipated) (ClinicalTrials.gov record NCT06682351, source copy `cardio:ctgov-nct06682351-2024-11-12`, retrieved 2026-10-26)
- Primary completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT06682351, source copy `cardio:ctgov-nct06682351-2024-11-12`, retrieved 2026-10-26)
- Completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT06682351, source copy `cardio:ctgov-nct06682351-2024-11-12`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT06682351, source copy `cardio:ctgov-nct06682351-2024-11-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06682351-2024-11-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention
- Condition: Prediabetes / Type 2 Diabetes
- Intervention (Drug): Metformin
- Intervention (Drug): GLP-1A
- Intervention (Dietary supplement): MED
- Lead sponsor: Stanford University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Prediabetes (`cardio:prediabetes`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Stanford University (`cardio:org-stanford-university`)

## Provenance

Content hash: 7b38901d37ec90e3c9bb00d7a0b6ce68fcdbfc5568960ed448a6d47378db92c1
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
